Pediatric Dermatology at Children's Wisconsin

The Dermatology Program at Children's Wisconsin welcomes children and adolescents with a wide range of skin conditions such as acne, birthmarks, psoriasis and nevi (moles).

Learn more

Sweating is a normal function that helps the body stay cool. However, some people have a medical problem that causes them to sweat too much. The medical term for this condition is hyperhidrosis.

Learn more

Children's Wisconsin dermatologists use a pulsed dye laser to treat children with certain dermatology conditions such as blood vessels, rosacea, pyogenic granulomas and vascular anomalies.

Learn more

Children's Wisconsin offers surgical skin procedures for infants, children and adolescents. We emphasize patient comfort and reducing anxiety during procedures. Following an initial consultation, procedures are scheduled with local/regional anesthesia or full anesthesia administered by a pediatric anesthesiologist. Surgeries are performed on the following types of lesions: small congenital nevi, cysts, miscellaneous nevi, atypical nevi and other skin tumors and growths.

Learn more

The purpose of this study is to determine if there are genes that are common in the cause of PHACE syndrome. Identification of causal gene(s) in PHACE syndrome would contribute to a better understanding of the molecular pathways involved in hemangiomas.

The purpose of this study is to establish a cohort of 30 subjects from ages 4 to 18 years of age; define the functional and neurodevelopmental outcome of PHACE syndrome and identify potential biomarkers that predict progressive vasculopathy, ischemic stroke, and neurodevelopmental impairment.

This study aims to better understand the natural history and clinical features of morphea. A retrospective review of our institutional experience with this disease is combined with a prospective registry. Standardized assessments will be completed at each visit. A tissue bank consisting of blood and skin samples will be accumulated over time to allow for translational research projects in the future.

A longitudinal cohort study of vascular anomalies associated with coagulopathy to describe clinical features, histopathological features, prognosis and therapeutic options. The goal is to provide an international resource for physicians and families by establishing diagnostic guidelines and developing standards of care for evaluation and treatment of kids with vascular anomalies associated with coagulopathy.

The primary goal of this pilot study is to identify potential biomarkers for patients with vascular malformations and variable clinical phenotypes that are potentially be tested in larger clinical trials. Patients with vascular malformations will be evaluated for global or mosaic growth abnormalities in an effort to assess the extent of these associations. Patients will be clinically evaluated for growth abnormalities and will have systematic molecular studies performed to detect abnormalities in the P13 kinase/AKT signaling pathway.

The purpose of this research is to develop a better understanding of the cause of genetic skin disorders. The researchers will also seek to determine if there is a relationship between the specific gene mutation and the skin changes or other medical problems

This is a prospective, multi-center, double-masked, randomized, efficacy, safety, and PK study. This study will serve as a tool to better identify the efficacy and safety of using topical timolol to treat infantile hemangiomas.

The primary objective of this study is to determine whether a single, easily measurable outcome correlates to therapeutic targets and quality of life goals for pediatric psoriasis patients.

The purpose of this study is to better characterize atopic dermatitis and document the real-world effectiveness and safety of treatments.

This study is part of the European PIP and USA Pediatric Study Plan, and it is intended to investigate the safety, efficacy, and PK of ixekizumab in pediatric subjects (children and adolescents).

This study leverages the availability of a validated series of instruments to measure the effect of highly visible, chronic skin disorders, including atopic dermatitis (AD), on patients 8 years of age and above in causing stigma and psychiatric issues, particularly anxiety and depression. These include measures in the PROMIS (Patient Reported Outcomes Measurement Information System) toolbox, among them short form assessments for pediatric anxiety, depression and social functioning, as well as a modified Neuro-QoL stigma instrument that includes skin-specific questions. Patient and parental instruments will be used to allow comparison in outcome assessment.